Please assess the completion status of the following clinical trial:

Trial Title: Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female patients older than 15 years and younger than 46 years.~2. Primary breast cancer (Stage I, II, or III).~3. Pathologically confirmed invasive breast carcinoma.~4. Negative hormone-receptor status. (Negative defined as ER- and PR- staining in less than 10% of tumor cells, or tumors with less than or equal to 3 fm/mg cytosol protein on ligand-binding or enzyme-linked immunoassay).~5. Premenopausal, verified before chemotherapy is begun as satisfying both:~   * Cyclic vaginal bleeding.~  * Follicle-stimulating hormone (FSH) is less than or equal to 15 IU/L. If patients are taking oral contraceptives, FSH must be measured 1-2 weeks after discontinuation. If FSH is greater than 15 and the patient has regular menses, gynecologic consultation will be required for a decision on premenopausal status.~6. Candidates for neoadjuvant and/or adjuvant chemotherapy for primary breast cancer.~7. Treatment with at least four (4) cycles of chemotherapy as planned.~8. Zubrod performance score of 0 or 1.~9. Must consent to preservation of their ovarian function and indicate their awareness of the investigational nature of this study, in keeping with institutional policy.~10. Willingness to use barrier contraception if sexually active.~Exclusion Criteria:~1. Pregnancy. Women must have a negative serum pregnancy test before initiation of injection.~2. Hypersensitivity to any GnRH analog.~3. Previous receipt of systemic chemotherapy.~4. To receive at least 4 cycles of neoadjuvant and/or adjuvant chemotherapy with CMF.~5. Stage IV breast cancer.~6. Prothrombin time (PT) and partial prothrombin time (PTT) with INR \> 1.5~7. Platelets \< 50,000/mm\^3

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 46 Years
- Healthy Volunteers: f

Study Arms:
- Goserelin (Type: EXPERIMENTAL): 3.6 mg subcutaneously 1 week before chemotherapy, then once a month until 3 weeks after chemotherapy.
- No Goserelin (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).